Japan Tobacco to buy British rival Gallaher for 2.25 tril. yen

Japan Tobacco to buy British rival Gallaher for 2.25 tril. yen

TOKYO, Japan - Japan Tobacco Inc. President Hiroshi Kimura tells a press conference at a Tokyo hotel on Dec. 15 the world's No. 3 tobacco company has reached a basic agreement to buy smaller rival Gallaher Group Plc of Britain for 2.25 trillion yen (about $19.08 billion). Iit would be the largest-ever corporate acquisition by a Japanese firm.

  • Product Code
  • ILEA001120178
  • Registered date
  • 2006/12/15 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2006 Kyodo News
  • Media size
  • 1864 × 2003 pixel
  • Resolution
  • dpi
  • Deployment size
  • 569.10(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos

    Sompo CEO to step down over Bigmotor insurance fraud scandal

    TOKYO, Japan, Jan. 26 Kyodo - Major Japanese insurance firm Sompo Holdings Inc. CEO Kengo Sakurada holds a press conference in Tokyo on Jan. 26, 2024, to announce he will step down at the end of March to take responsibility for the company's involvement in used car dealer Bigmotor Co.'s insurance fraud scandal. (Kyodo)
      Press conference by Japan's SBI, Taiwan's PSMC

      Press conference by Japan's SBI, Taiwan's PSMC

      Yoshitaka Kitao (L), chairman and president of Japanese financial group SBI Holdings Inc., and Frank Huang, chairman of Taiwan's Powerchip Semiconductor Manufacturing Corp., attend a press conference in Tokyo on Oct. 31, 2023. The two companies said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
        SBI Holdings Chairman Kitao

        SBI Holdings Chairman Kitao

        Yoshitaka Kitao, chairman and president of Japanese financial group SBI Holdings Inc., attends a press conference in Tokyo on Oct. 31, 2023. SBI and Taiwan's Powerchip Semiconductor Manufacturing Corp. said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
          Press conference by Japan's SBI, Taiwan's PSMC

          Press conference by Japan's SBI, Taiwan's PSMC

          Yoshitaka Kitao (L), chairman and president of Japanese financial group SBI Holdings Inc., and Frank Huang, chairman of Taiwan's Powerchip Semiconductor Manufacturing Corp., shake hands at a press conference in Tokyo on Oct. 31, 2023. The two companies said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
            SBI Holdings Chairman Kitao

            SBI Holdings Chairman Kitao

            Yoshitaka Kitao, chairman and president of Japanese financial group SBI Holdings Inc., attends a press conference in Tokyo on Oct. 31, 2023. SBI and Taiwan's Powerchip Semiconductor Manufacturing Corp. said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
              SBI Holdings Chairman Kitao

              SBI Holdings Chairman Kitao

              Yoshitaka Kitao, chairman and president of Japanese financial group SBI Holdings Inc., attends a press conference in Tokyo on Oct. 31, 2023. SBI and Taiwan's Powerchip Semiconductor Manufacturing Corp. said they have selected the village of Ohira in Miyagi Prefecture, northeastern Japan, as the location for their planned joint chip factory.
                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                  Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    U.S. regulators OK Alzheimer's drug developed by Japan's Eisai

                    Japanese pharmaceutical maker Eisai Co. CEO Haruo Naito holds a press conference in Tokyo on Jan. 7, 2023, a day after the U.S. Food and Drug Administration approved lecanemab, an Alzheimer's drug developed by his company and U.S. firm Biogen Inc. for treatment in the early stage of the fatal, brain-robbing disease.
                      Softbank Group logs record-high net profit for Japan firm

                      Softbank Group logs record-high net profit for Japan firm

                      SoftBank Group Corp. Chairman and CEO Masayoshi Son speaks at a press conference in Tokyo on May 12, 2021. The company said its net profit for the year ended March surged to 4.99 trillion yen ($46 billion), the highest level on record for a Japanese company.